Methods: Data were extracted from 200 of the 213 papers included in the Guidelines, (excluding the 13 in the preamble).
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Background: Liver transplantation (LT) is associated with risk for perioperative cardiovascular events. Although guideline recommended risk scores are well validated in noncardiac surgery, there is uncertainty regarding their utility in LT.
Methods: Consecutive adult patients undergoing LT at the Victorian Liver Transplantation Unit between 2010 and 2017 were evaluated. Perioperative 30-day major adverse cardiovascular events (MACE) and all-cause death were recorded from a prospectively maintained transplantation database and supplemented by electronic medical record review. Perioperative risk for each patient was calculated using the Revised Cardiac Risk Index (RCRI), Charlson Comorbidity Index (CCI) and American Society of Anaesthesiologists Score (ASA) and subsequently assessed for predictive validity.
Results: Among the 704 adult patients that underwent workup for LT, 462 proceeded to transplantation (mean age 52 ± 13, 67.5% male). A total of 51 (11%) patients had perioperative MACE within the 30-day post-operative period. Events included 26 episodes of cardiac failure, 15 resuscitated cardiac arrests, 16 acute coronary syndromes and 10 episodes of ventricular tachycardia. Predictive capability of the assessed scores is reported in Table 1 . The risk predictive ability of the RCRI, CCI and ASA scores were low, with all reporting an area under the curve (AUC) <0.60. A high risk score, as defined by guideline recommendations, demonstrated a modest negative predictive value (NPV) and a low positive predictive value (PPV).
Conclusion: Current preoperative risk prediction algorithms have poor predictive ability for cardiac events in a contemporary cohort of LT patients. Better risk prediction algorithms in this group of patients are warranted. Background: Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent form of HF, representing approximately half of the total burden of HF. In contrast to HF with reduced EF, no therapies have been proven effective at improving outcomes and quality of life to date.
Objectives: We hypothesised that modulation of the PDE-III using a novel oral formulation of milrinone might exert favourable effects HFpEF via pulmonary and systemic vasodilation and enhancement of ventricular relaxation. We assessed the safety and efficacy of oral milrinone on quality of life and functional outcomes in patients with HFpEF.
Methods: The MilHFPEF study was a randomised, double blind, placebo-controlled pilot study in patients with symptomatic HFpEF. Efficacy endpoints included changes from baseline in KCCQ summary score and 6-minute walk distance.
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Results: A total of 23 eligible patients completed the study. The KCCQ score improved significantly in milrinone treated patients compared to placebo (+10 ± 13 vs −3 ± 15, p = 0.046). 6MWD also tended to improve in the treatment group compared with placebo (+10 ± 62 vs −42 ± 77, p = 0.092). Heart rate (−1 ± 5 vs −2 ± 9bpm, p = 0.9) and systolic BP (−3 ± 18 vs +1 ± 12mmHg, p = 0.57) were unchanged. E/e' (−0.3 ± 3.0 vs. −1.9 ± 4.8, p = 0.38) was unchanged. One patient in the placebo arm was hospitalised for HF. Holter monitoring did not demonstrate a pro-arrhythmic effect of milrinone.
Conclusion: In this novel pilot study, extended release oral milrinone was well tolerated and associated with improved quality of life in patients with HFpEF. Further longer-term studies are warranted to establish the role of this therapeutic approach in HFpEF. Background: Primary PCI (pPCI) is preferred management with improved outcomes in STEMI [1] , however previous reviews demonstrate comparable, in-hospital results for early, pre-hospital thrombolysis in regional centres with large catchment zones [2] .
Methods: Retrospective analysis of patients presenting with STEMI at two outer metropolitan centres over a 5-year period (2014-2019), where PCI was available during working hours, with a strategy of pre-hospital thrombolysis other-wise. Patients were excluded if incomplete data precluded follow-up. The primary outcome was a composite of major adverse cardiac events (MACE) including myocardial infarction (MI), unplanned revascularisation, readmission for heart failure and all-cause mortality. Secondary outcomes included severe bleeding, TIMI-III flow rates and death from any cause. Follow up was conducted to 1-year from the index event.
Results: 450 consecutive patients presented with STEMI, with 425 analysed after exclusions. 117 (27.5%) underwent pPCI while 308 (72.5%) had initial thrombolysis. Average age was 63.9 years and 76.9% were male. Of the thrombolysis group, 56.5% successfully re-perfused while 43.5% required rescue PCI (rPCI) and 296 (96%) underwent coronary angiography. Rates of TIMI-III flow post angiogram were higher in the thrombolysis group 96.0% vs 85.9% (p = 0.0147). There were no significant differences in MACE at 1-month or 1-year or all-cause mortality. Major bleeding was higher at 1-month after thrombolysis 4.5% vs 2.6% (p = 0.36) but did not reach significance, likely due to inadequate power.
Conclusion: Our experience shows pre-hospital thrombolysis remains a safe alternative to pPCI, especially in regional centres, with no clinically significant differences in 1-and 12-month outcomes.
